ArriVent BioPharma, Inc. Common Stock Financial Flexibility Index
ArriVent BioPharma, Inc. Common Stock financial flexibility index. ArriVent BioPharma, Inc. Common Stock (AVBP) has a Financial Flexibility Index of -1.42x as of June 2026. Free cash flow of $-39.58 Million (operating CF $-39.58 Million minus capex $0.00) represents -1% of total liabilities ($27.88 Million).
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of ArriVent BioPharma, Inc. Common Stock (2021–2025)
Financial flexibility index of ArriVent BioPharma, Inc. Common Stock from 2021 to 2025. Historical Financial Flexibility Index trend for ArriVent BioPharma, Inc. Common Stock across 5 annual periods. Explore AVBP debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
ArriVent BioPharma, Inc. Common Stock Financial Flexibility Index by Year (2021–2025)
ArriVent BioPharma, Inc. Common Stock financial flexibility index by year from 2021 to 2025. Year-by-year free cash flow to debt coverage for ArriVent BioPharma, Inc. Common Stock. For the full cash flow conversion analysis, see AVBP cash flow metrics.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -6.19x | $-160.59 Million | $-160.59 Million | $25.95 Million | ▼ -52.4% |
| 2024 | -4.06x | $-70.21 Million | $-70.21 Million | $17.29 Million | ▲ +14.2% |
| 2023 | -4.73x | $-55.84 Million | $-55.84 Million | $11.80 Million | ▲ +9.2% |
| 2022 | -5.21x | $-43.63 Million | $-43.63 Million | $8.37 Million | ▲ +24.7% |
| 2021 | -6.92x | $-12.59 Million | $-12.59 Million | $1.82 Million | — |